Date: Tuesday, April 8, 2025 Time: 11:30 AM–1:00 PM ET
Moderator:
Nicola Napoli, MD, PhD, University Campus Bio-Medico di Roma
Dolores Shoback, MD, University of California – San Francisco
Speakers:
Marie Demay, MD, Professor of Medicine, Harvard Medical School
Anastassios Pittas, MD, Chief, Endocrinology, Diabetes and Metabolism; Co-Director, Diabetes and Lipid Center; Professor, Tufts University School of Medicine
Carlos Bernal-Mizrachi, MD, Chief of Medicine, Veterans Affairs St. Louis Health Care System; Professor of Medicine, Washington University St Louis
Description:
In this webinar leading experts will discuss the latest research, controversies, and clinical implications of vitamin D supplementation. Join us for the following presentations:
Dr. Marie Demay - "Making Sense of the Endocrine Society Vitamin D for the Prevention of Disease Guidelines"
Dr. Anastassios Pittas - “Vitamin D in People with Prediabetes”
Dr. Carlos Bernal-Mizrachi - “Pregnant Vitamin D Deficiency and the Epigenetic Programming of Immune Cells to Cause Insulin Resistance”
Each talk will last approximately 25 minutes, with 5 minutes for a question-and-answer session.
Learning Objectives:
Objective 1: To summarize key findings from evidence-based literature analyses of the effects of vitamin D on disease prevention in a healthy population
Objective 2: To evaluate the evidence on vitamin D for diabetes prevention in individuals with prediabetes, examining its potential role, clinical implications, and remaining controversies
Objective 3: To summarize the impact of in utero vitamin D deficiency on the epigenetic programming of hematopoietic stem cells (HSCs) and its subsequent effect on inducing insulin resistance (IR) and type 2 diabetes mellitus in offspring in humans and mice.
Date: March 26, 2024
Moderator: Joy Y. Wu, MD, PhD, Stanford University School of Medicine
Speakers: Patricia Juarez Camacho, PhD, CICESE, Mexico: “Bone Health and Metastatic Breast Cancer”
Serkin Park, DDS, MS, PhD, Korea University, Korea: "The Roles of Osteoblasts in Breast Cancer Bone Metastasis"
Azeez Farooki, MD, Memorial Sloan Kettering Cancer Center, United States: “Adjuvant and Antifracture Effects of Antiresorptives in Postmenopausal Breast Cancer”
Description: In this webinar, we will be able to understand the basic science of breast cancer and bone health, including breast bone metastasis mechanisms. Additionally, we will grasp the role of osteoblasts in the bone metastatic microenvironment and recognize their diagnostic potential. Lastly, we will discuss the adjuvant and antifracture effects of antiresorptives in postmenopausal breast cancer.
The presentation will be split into three sections focusing on basic science, translational science, and clinical practice. Each talk will last approximately 25 minutes, with 5 minutes for a question-and-answer session.
Learning Objectives:
Examine the basic science aspect of breast cancer and bone health, including mechanisms of breast bone metastasis.
Understand the role of osteoblasts in the metastatic bone microenvironment and recognize their diagnostic potential.
Discuss adjuvant and anti-fracture effects of antiresorptives in postmenopausal breast cancer.
Date: Tuesday, December 3, 2024 Time: 11:30 AM–1:00 PM ET
Moderator: Nicola C. Partridge, PhD, Rutgers University
Speakers:
Jean-Pierre Viladarga, PhD, University of Pittsburgh School of Medicine – “The Druggability of the PTH/PTHrP Receptor”
Jakob Hoeppner, MD, Massachusetts General Hospital and Harvard Medical School – “Novel Insights into PTH/PTHrP Receptor Signaling Regulation from Eiken Syndrome”
Alison Boyce, MD, National Institute of Dental and Craniofacial Research – “Treatment Strategies for Fibrous Dysplasia / McCune-Albright Syndrome”
Description:
In this webinar, we will understand the basic science of PTH/PTHrP receptor signaling and how to discover small non-peptidic molecules that might act through this receptor. Additionally, we will discuss Fibrous Dysplasia / McCune-Albright Syndrome (FD/MAS) and possible treatments and results of clinical trials. This lineup is intended to foster a logical progression from receptor targeting to disease model insights and clinical application. It is designed to engage both basic scientists and clinicians, fostering discussion on the latest research and therapeutic approaches in this field.
Each talk will last approximately 25 minutes, with 5 minutes for a question-and-answer session.
Learning Objectives:
Examine the basic science investigation of small allosteric molecules that modulate PTH/PTHrP receptor signaling.
Understand how PTHR1 signaling is fine-tuned by β-arrestins, responsible for specific biological functions of this receptor.
Discuss FD/MAS and emerging treatments, including results of clinical trials.
Collaborate and connect with peers on clinical care and research related to bone and mineral metabolism/disorders.
